New Zealand markets open in 2 hours 35 minutes

REGN Aug 2024 630.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.19000.0000 (0.00%)
As of 03:29PM EDT. Market open.
Full screen
Previous close3.1900
OpenN/A
Bid0.0000
Ask4.8000
Strike630.00
Expiry date2024-08-16
Day's range3.1900 - 3.1900
Contract rangeN/A
VolumeN/A
Open interest4
  • PR Newswire

    Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

    Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g

  • Simply Wall St.

    Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution

    The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...

  • Insider Monkey

    The Biggest Biotechnology Company in Europe

    We’ve recently covered a list of 20 Biggest Publicly-Traded Biotech Companies based on market caps that you can visit here. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering $3.88 trillion by 2030. The […]